Investment analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the stock.
Oragenics Stock Down 1.4 %
Shares of OGEN opened at $1.02 on Thursday. The stock has a market capitalization of $4.57 million, a P/E ratio of -0.11 and a beta of 0.31. Oragenics has a 1 year low of $1.00 and a 1 year high of $7.74. The firm’s 50 day moving average price is $1.56.
Oragenics (NYSE:OGEN – Get Free Report) last posted its quarterly earnings results on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also
- Five stocks we like better than Oragenics
- High Flyers: 3 Natural Gas Stocks for March 2022
- AMD is Down 35%. Now is the Time to Buy the Dip
- How Investors Can Find the Best Cheap Dividend Stocks
- Amazon Stands Tall: New Highs Are in Sight
- The 3 Best Blue-Chip Stocks to Buy Now
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
